Efficacy of Continuously Administered PEDF-Derived Synthetic Peptides against Osteosarcoma Growth and Metastasis

<table>Systemically delivered StVOrth-2 inhibits growth of orthotopic osteosarcoma. (a) Photomicrographs of mice showing left tumour-bearing hindlimbs. (b) Tumour volumes recorded at days 20, 23, 27, 30, and 34 after SaOS-2 intratibial injection (±SEM). *<svg height="11.0625" id="M3" style="vertical-align:-0.30096pt" version="1.1" viewbox="0 0 56.150002 11.0625" width="56.150002" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,11.0625)">
<g transform="translate(72,-63.15)">
<text transform="matrix(1,0,0,-1,-71.95,63.5)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑃</tspan>
<tspan style="font-size: 12.50px; " x="10.890113" y="0">&lt;</tspan>
<tspan style="font-size: 12.50px; " x="22.930502" y="0">0</tspan>
<tspan style="font-size: 12.50px; " x="29.182001" y="0">.</tspan>
<tspan style="font-size: 12.50px; " x="32.307751" y="0">0</tspan>
<tspan style="font-size: 12.50px; " x="38.559254" y="0">1</tspan>
</text>
</g>
</g>
</svg>, two-way ANOVA.</table>

BioMed Research International

fig3

Figure 3

Figure 3: Efficacy of Continuously Administered PEDF-Derived Synthetic Peptides against Osteosarcoma Growth and Metastasis 